We are live on
!
Find out more
KCM
Kingdon Capital Management Portfolio holdings
AUM
$911M
1-Year Est. Return
51.11%
This Fund
S&P 500
This Quarter
Est. Return
+26.25%
1 Year Est. Return
+51.11%
3 Year Est. Return
+185.44%
5 Year Est. Return
+284.29%
10 Year Est. Return
+2,022.7%
AUM
$925M
AUM Growth
+$33.9M
(+3.8%)
Cap. Flow
-$117M
Cap. Flow
% of AUM
-12.67%
Top 10 Holdings %
Top 10 Hldgs %
56.49%
Holding
80
New
21
Increased
13
Reduced
13
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$15.7M |
| 2 |
Flex
FLEX
|
+$12.1M |
| 3 |
Workday
WDAY
|
+$10.7M |
| 4 |
RADI
Radius Global Infrastructure, Inc. Class A Common Stock
RADI
|
+$9.76M |
| 5 |
Lithia Motors
LAD
|
+$7.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$28.4M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$26.9M |
| 3 |
Purple Innovation
PRPL
|
+$19.6M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$15.8M |
| 5 |
Nomad Foods
NOMD
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.01% |
| 2 | Consumer Discretionary | 12.8% |
| 3 | Communication Services | 9.57% |
| 4 | Industrials | 8.63% |
| 5 | Technology | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CARM
51
DELISTED
Carisma Therapeutics
CARM
| $2.31M | 0.25% |
85,584
-1,877
| -2% | -$47.6K |
|
52
CALL
PagerDuty
PD
$902M
| $2.18M | 0.24% |
+52,300
| New | +$1.78M |
|
|
EUCRU
53
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $2.13M | 0.23% |
+200,000
| New | +$2.03M |
|
|
XLRN
54
DELISTED
Acceleron Pharma
XLRN
| $1.92M | 0.21% |
15,000
-229,249
| -94% | -$26.9M |
|
55
California Resources
CRC
$4.62B
| $689K | 0.07% |
+29,199
| New | +$536K |
|
56
Exicure
XCUR
$8.54M
| $601K | 0.07% |
2,263
| – | – |
|
57
Aramark
ARMK
$14.7B
| – | – |
-685,664
| Closed | -$13.1M |
|
|
AZEK
58
DELISTED
The AZEK Co
AZEK
| – | – |
-220,000
| Closed | -$7.66M |
|
59
PUT
Biogen
BIIB
$30.7B
| – | – |
-100,000
| Closed | -$28.4M |
|
60
Caesars Entertainment
CZR
$6.14B
| – | – |
-97,700
| Closed | -$5.48M |
|
61
D.R. Horton
DHI
$42.3B
| – | – |
-136,950
| Closed | -$10.4M |
|
62
Danaher
DHR
$144B
| – | – |
-74,786
| Closed | -$14.3M |
|
63
PUT
Exelixis
EXEL
$13.4B
| – | – |
-306,300
| Closed | -$7.49M |
|
64
Expeditors International
EXPD
$23.2B
| – | – |
-93,000
| Closed | -$8.42M |
|
65
PUT
iShares Biotechnology ETF
IBB
$9.71B
| – | – |
-100,000
| Closed | -$13.5M |
|
|
LAZR
66
DELISTED
Luminar Technologies
LAZR
| – | – |
-25,400
| Closed | -$4.35M |
|
67
Lennar Class A
LEN
$21.2B
| – | – |
-132,017
| Closed | -$10.4M |
|
|
68
Merck
MRK
$318B
| – | – |
-358,206
| Closed | -$28.4M |
|
|
69
Nomad Foods
NOMD
$1.68B
| – | – |
-617,749
| Closed | -$15.7M |
|
70
Pan American Silver
PAAS
$21.6B
| – | – |
-195,850
| Closed | -$6.3M |
|
71
CALL
Pfizer
PFE
$153B
| – | – |
-210,800
| Closed | -$7.34M |
|
72
PUT
SAP
SAP
$238B
| – | – |
-55,500
| Closed | -$8.65M |
|
73
Simply Good Foods
SMPL
$982M
| – | – |
-437,458
| Closed | -$9.65M |
|
74
Trane Technologies
TT
$106B
| – | – |
-87,900
| Closed | -$10.7M |
|
75
CALL
Twilio
TWLO
$36.6B
| – | – |
-44,400
| Closed | -$11M |
|
Similar funds
GC
ICP
SAA
GIG
SI
PAMI
BDP
PTC
Kingdon Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Kingdon Capital Management held 80 positions worth $925M, up 3.8% from $891M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Kingdon Capital Management withdrew a net $117M in Q4 2020, closing 24 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $28.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, Kingdon Capital Management opened a new position in Baidu worth $22.9M.
- Kingdon Capital Management's largest Q4 2020 buy was Baidu: 105,815 shares worth $22.9M.
- Kingdon Capital Management added most to Lithia Motors in Q4 2020, an estimated $7.62M increase.
- Kingdon Capital Management's biggest Q4 2020 reduction was Acceleron Pharma, cutting an estimated $26.9M.
- Kingdon Capital Management fully exited Merck in Q4 2020, selling an estimated $28.4M.
- Kingdon Capital Management's ten largest holdings make up 56% of its $925M portfolio in Q4 2020.
- Kingdon Capital Management opened 21 new positions and closed 24 in Q4 2020.
- Kingdon Capital Management's portfolio value rose 3.8% quarter-over-quarter to $925M.
Based on Kingdon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.